@ScienceMagazine: Drug candidates that form covalent bonds with their targets were historically avoided because of toxicity concerns. How…
Summary
A new Science study reports streamlined access to an underexplored covalent warhead type with well-tempered reactivity, enabling practical use in drug discovery.
View Cached Full Text
Cached at: 07/30/26, 09:50 AM
Drug candidates that form covalent bonds with their targets were historically avoided because of toxicity concerns. However, covalent drugs with controlled reactivity are now recognized as promising agents that combine manageable safety with substantial advantages, including enhanced potency, prolonged target residence times, and access to challenging targets.
This shift is reflected in recent covalent drug approvals, particularly those targeting protein-phosphorylating enzymes (kinases) and cancer drivers such as the oncogenic protein KRAS. A central feature of these drugs is a “warhead” reacting with an amino acid residue in the target protein to form a covalent bond. Yet the repertoire of drug-like, chemically accessible reactive moieties remains limited.
In a new Science study, researchers report streamlined access to an underexplored warhead type with well-tempered reactivity that can be appended to complex scaffolds late in synthesis, enabling practical use in drug discovery.
Learn more in a new #SciencePerspective: https://scim.ag/4gZKvqa
Similar Articles
@nablabio: Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular pro…
Nabla Bio unveils JAM-2, a model for zero-shot drug design achieving atomic-precision, computationally designed multispecific antibodies and dual-variant KRAS multispecifics with high potency and selectivity, validated with Cryo-EM and wet-lab experiments.
@SurgeBiswas: New paper from the @nablabio team expanding generative drug design to multispecifics, the intracellular proteome, and p…
Nabla Bio's new paper (JAM-2) expands generative drug design to multispecifics and the intracellular proteome, achieving zero-shot design of a KRAS G12V-targeting bispecific that recruits T cells for picomolar cell killing.
Generating Developable 3D Molecules via Pocket-Conditioned Diffusion and Property-Aware Optimization
This paper introduces a novel diffusion-based generative model for structure-based drug design that decouples pocket and ligand representation learning and incorporates multi-scale interaction signals and property-aware optimization to generate developable 3D molecules with improved binding affinity and ADMET properties.
Building AI models that understand chemical principles
MIT Associate Professor Connor Coley discusses his work developing AI models to understand chemical principles and accelerate drug discovery by predicting reaction pathways and analyzing vast numbers of potential compounds.
ToolMol: Evolutionary Agentic Framework for Multi-objective Drug Discovery
ToolMol is an evolutionary agentic framework that combines a multi-objective genetic algorithm with an LLM-based operator to design small-molecule drugs, achieving state-of-the-art binding affinity and drug-likeness on multiple protein targets.